ER Inhibitors
1 drugsAbout ER
The Estrogen Receptor (ER) is a ligand-activated transcription factor within the nuclear receptor superfamily, crucial for regulating gene expression in response to estrogen hormones. It plays a key role in various physiological processes, making it a significant drug target.
ER is a therapeutic target despite the lack of genetic evidence directly linking it to specific diseases. Its involvement in multiple physiological processes has driven therapeutic interventions.
ER is targeted by 5 FDA-approved drugs, including CERIANNA, INLURIYO, ORSERDU, and DUAVEE (approved for two indications). All approved drugs are small molecules, with applications in oncology (3 drugs) and other therapeutic areas (2 drugs).
Strategic Insights
ℹ️ How we calculate- White space opportunity in Breastfeeding with only 1 trials.
Top ER Drugs
Four companies have approved drugs targeting ER, including GE HEALTHCARE, Eli Lilly, STEMLINE THERAP, and Pfizer.
The presence of multiple players suggests a moderately competitive market with potential for differentiation.
ER Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ER, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
ER Clinical Trials 1 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ER Drug Approval Timeline (2020 - 2020)
The first ER-targeting drug was approved in 2013, with the most recent approval in 2025.
The recent approval suggests continued interest and potential for further drug development targeting ER.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 25 clinical trials targeting ER.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities